Targeting specific immune cells to improve cancer treatment effectiveness
Targeting Unique Meyloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer Mutations
['FUNDING_CAREER'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-10874521
This study is looking at how some changes in melanoma cells can make them resistant to a common treatment called anti-PD-1 therapy, and it hopes to find ways to improve this treatment by focusing on certain immune cells that might help fight the cancer better for each patient.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-10874521 on ClinicalTrials.gov |
What this research studies
This research investigates how certain mutations in cancer cells can lead to resistance against anti-PD-1 therapy, which is commonly used to treat melanoma. By analyzing both mouse models and human melanoma biopsies, the study aims to identify unique populations of immunosuppressive myeloid cells that are recruited by these resistant cancer cells. The researchers will explore whether targeting these myeloid cells can enhance the effectiveness of anti-PD-1 therapy. Ultimately, the goal is to personalize immunotherapy based on individual patients' cancer mutations and immune cell profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients who have experienced resistance to anti-PD-1 therapy due to specific cancer mutations.
Not a fit: Patients with cancers other than melanoma or those who have not undergone anti-PD-1 therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for melanoma patients who currently do not respond to existing therapies.
How similar studies have performed: Other research has shown promise in targeting immune cell populations to overcome treatment resistance, suggesting that this approach may be viable.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MILLER, BRIAN C — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: MILLER, BRIAN C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Treatment, Cancers